We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Roche's Infectious Disease Portfolio To Include HCV Immunodiagnostics

By HospiMedica staff writers
Posted on 26 Nov 2007
Hepatitis C virus (HCV) infections frequently result in chronic liver disease. More...
They represent a major cause of death through the development of liver cirrhosis and liver cancer. HCV antibody tests are used for the primary diagnosis of HCV virus infection in patients with suspected liver disease. Positive anti-HCV results indicate the need for further investigation such as nucleic acid testing for viral RNA. Prognosis of HCV infection can be improved by anti-viral treatment, specifically interferon, and can be monitored using diagnostic tests.

Roche (Basel, Switzerland) announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. (Raritan, NJ, USA) and Novartis Vaccines & Diagnostics (Frimley/Camberley, UK) in the field of HCV diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for HCV in the field of immunodiagnostics. The agreement also includes cross licensing of patents owned by Roche Diagnostics. Financial terms of the deal were not disclosed.

The licensing agreement for HCV immunoassays will enable Roche Professional Diagnostics to expand its comprehensive product range in infectious diseases and to become a major player in this field, having already achieved a leading position in nucleic acid testing for hepatitis and retroviruses.

"We are pleased to have reached an agreement that provides Roche Diagnostics worldwide access to HCV immunoassays. This agreement will strengthen Roche's position in infectious disease diagnostics and will drive further growth of our immunoassay business worldwide,” commented Dirk Ehlers, head of Roche Professional Diagnostics.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology, and active in other therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders, and diseases of the central nervous system (CNS).


Related Links:
Roche
Ortho-Clinical Diagnostics
Novartis Vaccines & Diagnostics

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.